NCI Division of Cancer Treatment and Diagnosis:

An Overview of Resources Available for Extramural Scientists

Dr. Jason Cristofaro
Intellectual Property Advisor
National Cancer Institute
National Institutes of Health
NExT Pipeline:

Rapid Access to Intervention Development (RAID)

Drug Development Group (DDG)

Mission: provide resources and to develop treatments for cancer therapy and detection.

Adapted from Novartis Oncology
Overview of NExT Development Functions

• Directs R & D contracts to prioritize drug discovery and development (active role).
  – NCI-held IND: Drug Development Group (DDG).
  – Investigator-held IND: RAID, DCIDE.

• Contract Activities:
  – Discovery: screening, informatics, repositories, R*A*N*D.
  – Development: formulation, \textit{in vivo} testing, bulk synthesis, pharmacology, toxicology

• Access to External Cooperative group clinical trial resources

• DTP also manages grants pertinent to drug discovery, biochemical pharmacology (passive role).
The Chemical Biological Consortium: A New NCI Initiative
Developmental Therapeutics Program

❖ Provide access to DCTD pre-clinical contract research resources to academic/small business community (Managed by DCTD Staff)

❖ Examples of DTP “RAID-like” tasks:
  ✴ acquire/formulate bulk drug
  ✴ produce biologicals
  ✴ test efficacy of agent in animals
  ✴ pharmacology/toxicology studies

❖ Natural Products Branch – Natural Products Repository

❖ Screening activities/Repositories
RAID

- Provide access to DCTD pre-clinical contract research resources to academic/small business community ( Managed by DCTD Staff)

- Allow studies to occur under investigator or academic center sponsorship instead of NCI

- **Examples of RAID tasks:**
  - acquire/formulate bulk drug
  - produce biologicals
  - test efficacy of agent in animals
  - pharmacology/toxicology studies

- Bridge the gap between a LEAD DISCOVERY and a DRUG

- Traditional focus is on Academic researchers
Clinical Trial Evaluation Program

- Provide access to extramural cooperative group clinical trial resources

- Provides regulatory support for investigator-held and NCI held IND filings.

- Phase 1, Phase 2 and Phase 3 clinical trials all supported

- Generally requires a CRADA and an understanding of the IP option to collaborator.

- Traditional focus is on large pharma, but willing to provide assistance for smaller companies seeking resources for clinical trials.
Cancer Imaging Program (CIP)

- Imaging probes under current CIP IND
  - Assist PIs with regulatory issues
  - Facilitate access to some probes
  - PET Drugs: FLT, FMISO, FES, NaF

- Imaging probes under RDRC or other IND

- Extramural investigators – DCIDE Program

- ICBIO: Confidential forum for PIs with NCI/FDA/CMS

NExT Request for Proposal

Extramural scientists may apply for NCI Resources via the NExT Pipeline

https://dctd.cancer.gov/nextapp or
https://dctd.cancer.gov/nextregistration